U.S. Hospitality Stock News

NYSE:BXP
NYSE:BXPOffice REITs

A Look At Boston Properties (BXP) Valuation After Its Recent Share Price Rebound

Why BXP Stock Is on Investors’ Radar Today BXP (BXP) shares have recently shown mixed short term performance, with a gain of about 4% over the past week and roughly 15% over the past month, while the past 3 months remain weaker. See our latest analysis for BXP. At a share price of $59.84, BXP’s recent 15.3% 1 month share price return contrasts with its weaker year to date performance and slightly negative 1 year total shareholder return of 2.0%. This suggests momentum has picked up after a...
NYSEAM:SEB
NYSEAM:SEBFood

Seaboard (SEB) Margin Rebound to 5.9% Challenges Longstanding Earnings Bear Case

Seaboard's Q1 2026 Earnings Snapshot Seaboard (SEB) opened 2026 with Q1 total revenue of US$2.4b, basic EPS of US$124.24 and net income of US$119m, setting a fresh reference point against last year’s sharp earnings rebound. Over recent quarters the company has seen quarterly revenue move from US$2.316b in Q1 2025 to around the US$2.4b range in Q1 2026. Basic EPS shifted from US$32.95 to US$124.24. Trailing twelve month EPS reached US$606.79 alongside net income of US$583m on US$9.83b of...
NYSE:RYAM
NYSE:RYAMChemicals

Rayonier Advanced Materials (RYAM) Q1 Loss Worsening Pressures Bullish Margin Recovery Narratives

Rayonier Advanced Materials (RYAM) opened 2026 with Q1 revenue of US$319 million and a basic EPS loss of US$1.21, alongside trailing 12 month revenue of about US$1.4 billion and a basic EPS loss of US$7.08. Over recent quarters the company has seen revenue move from US$422.5 million in Q4 2024 to US$355.9 million in Q1 2025, US$340.0 million in Q2 2025, US$352.8 million in Q3 2025, US$417.5 million in Q4 2025 and now US$319 million in Q1 2026, while quarterly basic EPS losses have ranged...
NYSE:DVN
NYSE:DVNOil and Gas

Devon Energy (DVN) Margin Squeeze And EPS Drop Test Bullish Efficiency Narrative

Devon Energy (DVN) opened 2026 with Q1 revenue of US$4.3b and basic EPS of US$0.19 on net income of US$120m, setting a cautious tone for the new year. Over the past few quarters, the company has seen revenue move between US$3.8b and US$4.3b, while quarterly EPS has ranged from about US$0.77 to US$1.42. This has contributed to trailing twelve month EPS of US$3.63 on revenue of US$16.0b. Investors are therefore likely to focus on how much of that top line converts into profit as margins adjust...
NasdaqGS:GRAB
NasdaqGS:GRABTransportation

Grab Holdings (NasdaqGS:GRAB) Net Margin Breakout Tests Bullish Profitability Narrative

Grab Holdings (NasdaqGS:GRAB) opened 2026 with Q1 revenue of US$955 million and basic EPS of US$0.03, setting a clear marker for how its ride hailing and delivery platform is currently translating scale into per share earnings. The company has seen quarterly revenue move from US$773 million in Q1 2025 to US$955 million in Q1 2026, while basic EPS has shifted from US$0.01 to US$0.03 over the same period. Trailing twelve month EPS now sits at US$0.09 on revenue of US$3.6 billion, giving...
NasdaqGS:BVS
NasdaqGS:BVSMedical Equipment

Bioventus (BVS) Q1 EPS Holds Profitability But Tests Bullish Margin Narratives

Bioventus (BVS) opened 2026 with Q1 revenue of US$132.1 million and basic EPS of US$0.05, alongside trailing twelve month revenue of US$576.3 million and basic EPS of US$0.43 that reflect a period of positive net income. Over recent quarters the company has seen revenue range from US$123.9 million to US$157.9 million, while basic EPS moved from a loss of US$0.04 in early 2025 to US$0.22 in Q4 2025 and US$0.05 in the latest quarter, setting up a narrative that now hinges on how durable these...
NYSE:CTVA
NYSE:CTVAChemicals

Corteva (CTVA) Q1 EPS Beat Strengthens Bullish Margin Narrative Despite Valuation Debate

Q1 2026 headline results and setup Corteva (CTVA) opened 2026 with Q1 revenue of US$4.9 billion and basic EPS of US$1.07, with trailing twelve month net income of US$1.25 billion giving investors a fuller view of the current earnings run rate. The company reported quarterly revenue of US$4.42 billion in Q1 2025 and US$4.91 billion in Q1 2026, while basic EPS moved from US$0.97 to US$1.07 over the same period as trailing net profit margins held close to 7%. With earnings growth forecasts...
NYSE:SOLV
NYSE:SOLVMedical Equipment

Solventum (SOLV) Q1 Earnings Slump As Margin Compression Tests Bullish Narratives

Solventum (SOLV) opened Q1 2026 with revenue of US$2.0 billion and basic EPS of US$0.07, putting fresh numbers on the table for investors focused on how its earnings profile is evolving. Over the past few reporting periods, revenue has moved between US$2.1 billion in Q1 2025 and US$2.0 billion in Q1 2026, while basic EPS shifted from US$0.79 in Q1 2025 to US$0.07 in the latest quarter, with the trailing twelve months showing revenue of US$8.3 billion and basic EPS of US$8.22. This mix of...
NasdaqGS:LAB
NasdaqGS:LABLife Sciences

Standard BioTools (LAB) Premium P/S Multiple Tests Narratives After Another Quarterly Loss

Standard BioTools (LAB) has kicked off Q1 2026 with revenue of about US$21.1 million and a basic EPS loss of roughly US$0.04. This sets a cautious tone around how much of that top line is flowing through to the bottom line. The company has seen quarterly revenue move between roughly US$19.6 million and US$24.8 million since Q4 2024, while basic EPS has ranged from a loss of about US$0.08 to a profit of roughly US$0.04 over the same period. This underscores how sensitive margins have been to...
NasdaqGS:TEM
NasdaqGS:TEMLife Sciences

Tempus AI (TEM) Q1 Loss Widens To US$0.70 EPS And Reinforces Bearish Profitability Concerns

Tempus AI (TEM) opened Q1 2026 with revenue of US$348.1 million and a basic EPS loss of US$0.70, while trailing 12 month figures show US$1.4 billion in revenue and a basic EPS loss of US$1.72. This keeps the focus firmly on scaling rather than profitability. Over recent quarters the company has seen revenue move from US$255.7 million in Q1 2025 to US$348.1 million in Q1 2026, with basic EPS losses ranging between US$0.25 and US$0.70 per quarter across that period. For you as an investor, this...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

CRISPR Therapeutics Expands Pipeline As CASGEVY Grows And Cash Pile Rises

CRISPR Therapeutics (NasdaqGM:CRSP) has expanded its lead CAR-T program, zugo-cel, into new autoimmune disease indications. The company advanced multiple in vivo liver-directed gene editing and siRNA programs into clinical development. CASGEVY, its gene-editing therapy, continues to see commercial traction, and a recent regulatory filing aims to extend its label to younger pediatric patients. A major convertible notes offering has strengthened the balance sheet and is funding a broader...
NasdaqGS:INTA
NasdaqGS:INTASoftware

Intapp (INTA) Q3 Loss Of US$15.5 Million Tests Profitability Narrative

Intapp (NasdaqGS:INTA) has reported Q3 2026 revenue of US$146.0 million with a basic EPS loss of US$0.20, alongside net income excluding extra items of a US$15.5 million loss. The company has seen quarterly revenue progress from US$121.2 million in Q2 2025 to US$129.1 million in Q3 2025 and US$146.0 million in Q3 2026. Over the same periods, basic EPS moved from a US$0.13 loss to a US$0.04 loss and then a US$0.20 loss, setting up this quarter as another test of how quickly margins can move...
NasdaqGS:WTW
NasdaqGS:WTWInsurance

Is It Time To Reassess Willis Towers Watson (WTW) After The Recent Share Price Slump?

If you are wondering whether Willis Towers Watson at around US$252 per share looks attractively priced or just fairly valued, the recent share performance gives some important clues. The stock has seen a 13.0% decline over the past week, a 13.3% decline over the past month, a 22.6% decline year to date, and a 16.5% decline over the last year. However, the 3 year and 5 year returns of 15.0% and 3.3% respectively paint a different picture over longer periods. Recent news coverage has focused...
NasdaqGM:BWMN
NasdaqGM:BWMNConstruction

Bowman Consulting Group (BWMN) Quarterly Loss Revives Bearish Margin Concerns

Bowman Consulting Group (BWMN) opened Q1 2026 with revenue of US$126.5 million and a basic EPS loss of US$0.22, alongside trailing twelve month EPS of US$0.62 on US$503.6 million of revenue. Over the past year, the company has seen revenue move from US$444.6 million to US$503.6 million on a trailing basis, while EPS shifted from US$0.16 to US$0.62, giving investors a clear view of how the top line and per share earnings have tracked together. Taken together with a trailing net margin that now...
NasdaqCM:GSM
NasdaqCM:GSMMetals and Mining

Ferroglobe (GSM) Q1 Loss Narrows To US$7.1 Million Challenging Bearish Narratives

Ferroglobe (NasdaqCM:GSM) opened 2026 with Q1 revenue of US$347.7 million and a basic EPS loss of US$0.04, alongside a trailing 12 month net loss of US$111.3 million on revenue of US$1.4 billion. Over recent quarters the company has seen revenue move between US$307.2 million and US$386.9 million, while quarterly basic EPS has ranged from a loss of US$0.04 to a loss of US$0.43 as profitability remained under pressure and margins stayed in the red. See our full analysis for Ferroglobe. With the...
NasdaqGS:ONC
NasdaqGS:ONCBiotechs

BeOne Medicines (ONC) EPS Surge Tests Bullish Profitability Narratives

BeOne Medicines (ONC) opened 2026 with Q1 revenue of US$1.5b and basic EPS of US$2.05, alongside net income of US$227.4 million. This sets a clear marker for how the business is currently converting its top line into earnings. Over the past year, the company has seen quarterly revenue move from US$1.1b in Q1 2025 to US$1.5b in Q1 2026, while basic EPS shifted from essentially flat at US$0.01 to US$2.05. This gives investors a straightforward read on how profitability is tracking against the...
NasdaqGS:HCKT
NasdaqGS:HCKTIT

Hackett Group Q1 2026 Margin Compression Reinforces Bearish Narrative On Earnings Rebound

Hackett Group (HCKT) has opened Q1 2026 with total revenue of US$67.8 million and basic EPS of US$0.17, alongside trailing twelve month revenue of US$292.5 million and EPS of US$0.53. These figures sit against a net profit margin of 4.8% versus 7.8% a year earlier. Over recent quarters the company has seen quarterly revenue move from US$76.2 million in Q1 2025 to US$77.6 million in Q2 2025, US$72.2 million in Q3 2025 and US$74.8 million in Q4 2025, before landing at US$67.8 million in Q1...
NYSE:UWMC
NYSE:UWMCDiversified Financial

UWM Holdings (UWMC) Q1 Profitability Turn Supports Bullish Earnings Momentum Narratives

UWM Holdings (UWMC) opened 2026 with Q1 revenue of US$752.9 million and basic EPS of US$0.09, alongside trailing twelve month revenue of US$4.0 billion and basic EPS of US$0.27 that reflect the company’s move into profitability over the past year. The company has seen quarterly revenue range from US$613.4 million in Q1 2025 to US$1.0 billion in Q4 2025, with EPS swinging from a loss of US$0.08 in Q1 2025 to a profit of US$0.11 in Q2 2025 before settling at US$0.09 this quarter. This sets up a...
NasdaqGS:LITE
NasdaqGS:LITECommunications

Lumentum Holdings (LITE) Profitability Rebound Tests Bullish Growth Narratives In Q3 2026

Lumentum Holdings (LITE) opened Q3 2026 with revenue of US$808.4 million and basic EPS of US$1.99, supported by net income of US$142.5 million. The company has seen revenue move from US$402.2 million in Q2 2025 to US$808.4 million in Q3 2026, while basic EPS shifted from a loss of US$0.88 to a gain of US$1.99. Trailing twelve month EPS stands at US$6.21 on revenue of US$2.5 billion. This combination of profitability and revenue scale puts the focus firmly on margins as results season...
NYSE:BBWI
NYSE:BBWISpecialty Retail

Is Bath & Body Works (BBWI) Pricing Reflect Its Recent Share Price Swings?

Wondering if Bath & Body Works at around US$19.20 is a bargain or a value trap? This article focuses squarely on what the current price may be implying about the stock. The stock has risen 4.7% over the last week and 6.0% over the last month, yet year to date it shows a 7.4% decline and the 1 year return stands at 34.8% lower. This pattern may catch the eye of value focused investors. Recent coverage around specialty retail and consumer discretionary spending has put companies like Bath &...
NasdaqGS:LINE
NasdaqGS:LINEIndustrial REITs

Lineage (LINE) FFO Turns Positive Testing Bearish Views On Persistent EPS Losses

Lineage (LINE) opened Q1 2026 with revenue of US$1.3 billion and a basic EPS loss of US$0.20. On a trailing 12 month basis, revenue stood at US$5.4 billion and basic EPS was a loss of US$0.63, alongside trailing 12 month revenue growth of 4.6% a year versus 11.3% for the broader US market. Over recent quarters, revenue has moved in a narrow band between US$1.29 billion and US$1.38 billion, while quarterly basic EPS has ranged from a loss of US$0.44 to a small profit of roughly US$0.03. This...
NYSE:PLOW
NYSE:PLOWMachinery

Is It Too Late To Consider Douglas Dynamics (PLOW) After Its 84% One Year Surge?

Some investors may be considering whether Douglas Dynamics at around US$45.42 is still offering value after a strong run, or whether much of the opportunity is already reflected in the current share price. The stock has recorded returns of 2.8% over 7 days, 8.1% over 30 days, 37.7% year to date and 83.6% over 1 year. This puts recent price action front and center for anyone weighing the balance between potential and risk. Recent coverage has highlighted Douglas Dynamics as a Machinery sector...
NYSE:UBER
NYSE:UBERTransportation

Uber Technologies (UBER) Q1 Margin Compression Tests Bullish Profitability Narratives

Uber Technologies (UBER) opened 2026 with Q1 revenue of US$13.2b and basic EPS of US$0.13, setting the tone for how investors assess profit quality after a year in which trailing twelve month EPS sat at US$4.12. The company reported quarterly revenue increasing from US$11.5b in Q1 2025 to US$13.2b in Q1 2026, while basic EPS moved from US$0.85 to US$0.13 over the same period, against a trailing net income base of US$8.5b. With margins firmly in focus after the past year's compression, this...
NasdaqGS:MDLN
NasdaqGS:MDLNMedical Equipment

Medline (MDLN) Margin Squeeze In Q1 2026 Challenges Bullish Growth Narratives

Medline (MDLN) opened 2026 by reporting Q1 revenue of about US$7.4b and net income of US$129m, with basic EPS of US$0.16 against a trailing twelve month EPS of US$1.14 that was generated on US$29.1b of revenue and US$966m of net income. Over the past few quarters the company has seen revenue move from US$6.8b in Q4 2024 to US$6.8b in Q1 2025, then to US$7.1b in Q3 2025, US$7.8b in Q4 2025 and finally US$7.4b in Q1 2026, while quarterly basic EPS shifted from US$0.02 in Q4 2024 to US$0.02 in...